Q-omics provides the consensus-scored VEGFA profile across patient tissues and cancer cell-line models. VEGFA expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, VEGFA is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, VEGFA RNA expression shows 19,754 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRP, KIRC, and ACC as cancer lineages where VEGFA shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for VEGFA — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes VEGFA survival associations across molecular data types. VEGFA RNA expression shows survival associations in the most cancer types (24), followed by mutation status (7) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible VEGFA RNA expression–survival associations across cancer types. High VEGFA expression shows unfavorable associations in KIRP, UVM, CESC, BRCA, LGG and LIHC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for VEGFA RNA expression.
This table summarizes VEGFA tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for VEGFA. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. VEGFA shows lower tumor expression in THCA and higher tumor expression in KIRC, COAD, HNSC, STAD and LIHC. The KIRC box plot shows higher VEGFA RNA expression in tumor versus normal tissue (log2 FC = +3.460, t-test p < 0.001).
This table shows molecular features associated with VEGFA in patient tissues and cancer cell lines. In patient samples, VEGFA shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, VEGFA RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
